Atazanavir (Reyataz)
Atazanavir
Equity Pharmaceutical (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Equity Pharmaceutical (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Reyataz 150 MG EACH CAPSULE CONTAINS ATAZANAVIR SULPHATE EQUIVALENT TO ATAZANAVIR 150,0 mg | 150 mg | A390088A39/20.2.8/0088 | Cancelled | Not determined | None |
| Reyataz 200 MG EACH CAPSULE CONTAINS ATAZANAVIR SULPHATE EQUIVALENT TO ATAZANAVIR 200,0 mg | 200 mg | A390089A39/20.2.8/0089 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Atazanavir
Consolidated Schedules 06 July 2026, line 5370
S4: Ritonavir
Consolidated Schedules 06 July 2026, line 7820
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.